ClinicalTrials.gg
TerminatedNCT04619433Updated Sep 23, 2025

A Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects With NSCLC.

A Phase 3 interventional study of Camrelizumab;Pemetrexed and Carboplatin; Famitinib; and Camrelizumab;Pemetrexed and Carboplatin;Placebo in Non-squamous Non-small-cell Lung Cancer, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Terminated at 7 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-09-23.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 3, Interventional, and Treatment

Why this study was terminated
Terminated by Sponsor

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing camrelizumab in Carcinoma, Non-Small-Cell Lung — 6 open to participants now, 7 under way, 1 of them phase 3. camrelizumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
17th of 27
48 · median 58
Started
2021
with 6 others
Phase 3
5 of 27
1 open now
Registered
14th of 27
by date
Lead sponsor
7 of 27
Jiangsu HengRui Medicine Co., Ltd.

Among the 27 studies testing camrelizumab in Carcinoma, Non-Small-Cell Lung, this one is the 17th largest by enrollment, is one of 7 that started in 2021, is one of 5 in phase 3, and was the 14th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

6 of the 27 studies testing camrelizumab in Carcinoma, Non-Small-Cell Lung are open now, in 2 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Where they have run

About camrelizumab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing camrelizumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The study is being conducted to evaluate the efficacy and safety of SHR-1210 in combination with Famitinib plus chemotherapy in subjects with NSCLC.

Read the detailed description

The study is being conducted to evaluate the efficacy and safety of Camrelizumab in combination with Famitinib plus chemotherapy in subjects with NSCLC.

03

Conditions studied

  • Non-squamous Non-small-cell Lung Cancer
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed Form, male or female, 18-70 years of age.
  2. or cytologically confirmed, Stage IIIB-IV non-squamous NSCLC
  3. EGFR mutation and ALK rearrangement status must be negative.
  4. No prior system chemotherapy for advanced/ NSCLC.
  5. Measurable diseaseas defined by v1.1.
  6. performance status of 0 or 1.
  7. Has a of at least 3 months.
  8. Adequater organ function.
  9. Female subjects of must have a negative serum pregnancy test within 7 days prior to the first dose, and be willing to use a recognized effective measure during the study and within 3 months after the last dose of the study drug; Male subjects with partners of childbearing potential must either be surgically sterilized or agree to take effective contraceptive measures during the study and within 3 months after the last dose of the study drug.

Exclusion criteria

Exclusion Criteria:

1、 Cancer-Specific Exclusions

  1. Other histological types of non-small cell lung cancer.
  2. Subjects with carcinomatous meningitis and spinal cord compression.
  3. Subjects with untreated central nervous system (CNS) .
  4. Subjects who can be treated with surgical resection or radical radiotherapy.
  5. Subjects who previously received (L1) or CTLA4 monoclonal antibody, VEGF or VEGFR signaling pathway single target/multiple target inhibitor or monoclonal antibodies.

2. Medical history and complications

  1. Subjects with any active, known, or suspected diseases.
  2. Subjects who require systemic prednisone (> 10 mg/day or equivalent) or other within 14 days prior to the first dose.
  3. Subjects who received cancer vaccines or other immunostimulatory anti-cancer agents (interferon, interleukin, thymosin, or immune cell therapy) within 1 month prior to the first dose.
  4. Subjects who received anti-cancer TCM within 14 days prior to the first dose.
  5. Subjects who are in another clinical study or last participated (last dose) in a clinical study less than 4 weeks (or 5 half-lives of the study drug) from the first dose, whichever is shorter.
  6. Subjects who are expected to require other forms of anti-cancer treatment during the study.
  7. Subjects who received major surgery within 4 weeks prior to the first dose, non-thoracic radiation therapy > 30 Gy within 4 weeks prior to the first dose, thoracic radiation therapy > 30 Gy within 24 weeks prior to the first dose, or palliative radiation ≤ 30 Gy within 2 weeks prior to the first dose, and failed to recover from the toxicities and/or complications of these interventions to NCI-CTC AE Grade ≤ 1 (except for alopecia and fatigue). Palliative radiotherapy for symptomatic control is permitted, but must be completed within 2 weeks prior to starting the study treatment.
  8. Subjects highly suspected of interstitial lung disease, or with conditions that may interfere with the testing or management of suspected treatment-related pulmonary toxicities, or other moderate to severe lung diseases that seriously affect pulmonary function.
  9. Subjects with a history of malignant tumors.
  10. Subjects with severe cardiovascular disease.
  11. Subjectss with hypertension which cannot be well controlled by antihypertensives.
  12. Subjects with hemorrhage or clear bleeding tendency within 3 month prior to the first dose.
  13. Events of arterial/venous thrombosis within 6 months prior to the first dose.
  14. Subjects who require long-term anticoagulant therapy with warfarin or heparin.
  15. Subjects who require long-term antiplatelet therapy.
  16. Significant vascular invasions or a high possibility of significant vascular invasions that may cause bleeding as determined by the investigator during treatment.
  17. Subjects with active pulmonary tuberculosis (TB).
  18. Subjects with serious infection within 4 weeks prior to the first dose, including but not limited to infective complications, bacteremia, and severe pneumonia that require hospitalization.
  19. Subjects who prepare to receive or have previously received tissue/organ transplants.
  20. Gastrointestinal disorder or surgical history that may affect the swallowing, digestion, and absorption of the oral drug as determined by the investigator.
  21. Subjects who plan to receive or have received within 30 days prior to the first dose.
  22. Subjects with uncontrolled cancer pain.

3. Physical examination and laboratory tests

  1. Known history of (HIV) seropositive status or acquired immunodeficiency syndrome (AIDS).
  2. Active virus or virus infection.
  3. Subjects with uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage.

4. Allergies and adverse drug reactions

  1. Severe allergic reactions to other monoclonal antibodies.
  2. Allergy or intolerance during an infusion.
  3. History of severe allergies to pemetrexed, carboplatin, or their premedications.

5. Subjects with mental illness, alcohol abuse, inability to quit smoking, and drug or substance abuse.

6. Based on the investigator's judgment, subjects with a history or current evidence of diseases, treatments, or laboratory abnormalities that may affect study results, interfere with study procedures, or are not in the best interests of the subjects, should be excluded.

Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Treatment group A

    Intervention Drug: Camrelizumab; Pemetrexed; Carboplatin; Famitinib

    Drug: Camrelizumab;Pemetrexed and Carboplatin; Famitinib;

  • Placebo comparator
    Treatment group B

    Intervention Drug: Camrelizumab; Pemetrexed; Carboplatin; Placebo

    Drug: Camrelizumab;Pemetrexed and Carboplatin;Placebo

Interventions

  • DrugCamrelizumab;Pemetrexed and Carboplatin; Famitinib;

    Drug pages: Camrelizumab · Pemetrexed · Carboplatin · Famitinib

    Part 1: Drug: Camrelizumab; Pemetrexed; Carboplatin; Famitinib Part 2: Drug: Camrelizumab; Pemetrexed; Carboplatin; Famitinib

    Also known as: SHR1210

  • DrugCamrelizumab;Pemetrexed and Carboplatin;Placebo

    Part 2: Drug: Camrelizumab; Pemetrexed; Carboplatin; Placebo

    Also known as: SHR1210

06

What researchers measure

Primary outcomes

  1. Part 1:Serum concentrations of Camrelizumab

    Time frame: Cycle 2; each cycle is 21 days (up to 42 days)

  2. Part 1:Plasma concentrations of Famitinib

    Time frame: Cycle 2; each cycle is 21 days (up to 42 days)

  3. Part 1:Area Under the Plasma Concentration Versus Time Curve (AUC) of Famitinib.

    Time frame: Cycle 2; each cycle is 21 days (up to 42 days)

  4. Part 1:Maximum Concentration (Cmax) of Famitinib.

    Time frame: Cycle 2; each cycle is 21 days (up to 42 days)

  5. Part 1:Time to Maximum Concentration (Tmax) of Famitinib.

    Time frame: Cycle 2; each cycle is 21 days (up to 42 days)

  6. Part 1:Half-life (t1/2 z) of Famitinib.

    Time frame: Cycle 2; each cycle is 21 days (up to 42 days)

  7. Part 1:Apparent Clearance (CL/F) of Famitinib

    Time frame: Cycle 2; each cycle is 21 days (up to 42 days)

  8. Part 1:Vz/F of Famitinib.

    Time frame: Cycle 2; each cycle is 21 days (up to 42 days)

  9. Part 2: Progression-free Survival (PFS) as Assessed by BICR according to RECIST 1.1.

    Time frame: up to 24 months

Secondary outcomes

  1. Part 1:Objective Response Rate (ORR) as Assessed by investigators

    Time frame: Cycle 2; each cycle is 21 days (up to 42 days)

  2. Part 1:Duration of Response (DOR) as Assessed by investigators

    Time frame: Cycle 2; each cycle is 21 days (up to 42 days)

  3. Part 1:Progression-free Survival (PFS) as Assessed by investigators

    Time frame: Cycle 2; each cycle is 21 days (up to 42 days)

  4. Part 1:Overall Survival (OS).

    Time frame: Up to approximately 60 months

  5. Part 2:Overall Survival (OS)

    Time frame: Up to approximately 60 months

  6. Part 2:Progression-free Survival (PFS) as Assessed by investigators according to RECIST 1.1.

    Time frame: up to 24 months

  7. Part 2:Objective Response Rate (ORR) as Assessed by investigators and BICR according to RECIST 1.1

    Time frame: up to 24 months

  8. Part 2:Duration of Response (DOR) as Assessed by investigators and BICR according to RECIST 1.1

    Time frame: up to 24 months

  9. Part 2:Disease Control Rate(DCR) as Assessed by investigators and BICR according to RECIST 1.1

    Time frame: up to 24 months

  10. Part 2:Number of Participants With Adverse Events and Serious Adverse Event as Assessed by CTCAE v5.0.

    Time frame: up to 24 months

07

Study locations

7 sites
  • Beijing Cancer Hosipital
    Beijing, Beijing Municipality 100089, China
  • Henan Cancer Hospital
    Zhengzhou, Henan 450003, China
  • Hubei Cancer Hospita
    Wuhan, Hubei 430079, China
  • Shengjing Hospita of China Medical University
    Shenyang, Liaoning 110022, China
  • Shanghai Lung Hospital
    Shanghai, Shanghai Municipality 200433, China
  • West China Hospital,Sichuan University
    Chengdu, Sichuan 610000, China
  • Tianjin Medical University Cancer Institute and Hospital
    Tianjin, Tianjin Municipality 300060, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2021 to primary completion in Aug 2025, 54 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2020
First posted
Nov 6, 2020
StartActual
Feb 1, 2021
Primary completionActual
Aug 16, 2025
CompletionActual
Aug 16, 2025
Last update
Sep 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04619433
Responsible party
Sponsor
First posted
Nov 6, 2020
Start date
Feb 1, 2021
Primary completion
Aug 16, 2025
Completion
Aug 16, 2025
Last update
Sep 23, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Camrelizumab · Pemetrexed · Carboplatin · Famitinib

Start the discussion